Keyphrases
Cyclic GMP
100%
NO-cGMP
100%
Translational Potential
100%
PDE5 Inhibitors
66%
Human Disease
33%
Signaling Molecules
33%
Clinical Evaluation
33%
First-in-class
33%
Therapeutic Targeting
33%
Molecular Events
33%
Endotoxic Shock
33%
Downstream Signaling
33%
Diabetic Cardiomyopathy
33%
Pulmonary Hypertension
33%
Haem
33%
Cardiovascular Effects
33%
Prosthetic Group
33%
Myocardial Failure
33%
Complex Pathways
33%
Organic Nitrates
33%
Erectile Dysfunction
33%
Becker muscular Dystrophy
33%
Nobel Prize
33%
Experimental Disease Models
33%
Novel Indications
33%
Well-founded
33%
Medicine and Dentistry
Phosphodiesterase V Inhibitor
100%
Clinical Trial
50%
Disease
50%
Medicine
50%
Mediator
50%
Heme
50%
Septic Shock
50%
Signaling Molecule
50%
Diabetic Cardiomyopathy
50%
Pulmonary Hypertension
50%
Prosthetics
50%
Congestive Heart Failure
50%
Cardiovascular Effect
50%
Disease Model
50%
Erectile Dysfunction
50%
Organic Nitrate
50%
Experimental Disease
50%
Becker Muscular Dystrophy
50%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphodiesterase V Inhibitor
100%
Clinical Trial
50%
Disease
50%
Congestive Heart Failure
50%
Septic Shock
50%
Disease Model
50%
Diabetic Cardiomyopathy
50%
Heme
50%
Pulmonary Hypertension
50%
Experimental Disease
50%
Organic Nitrate
50%
Erectile Dysfunction
50%
Becker Muscular Dystrophy
50%